Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Cancer treatments can instigate ocular surface disease and other deleterious ocular side effects that optometrists can oversee and manage.

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

A DAILY pill for the most common form of bladder cancer has been given the green light for NHS use. Erdafitinib, which blocks ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

Hundreds will benefit after the first targeted treatment for the most common form of bladder cancer was given the green light ...

The drug, recommended by NICE, works by blocking certain proteins to slow down or stop the growth of cancer cells ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...